Table 1. Patient characteristics, n=109.
| Patient characteristic | Distribution† | Range |
|---|---|---|
| Age in years | 56 [27] | 23–78 |
| Sex, males | 59 (54) | – |
| Race | White: 73 (67) | – |
| African American: 13 (12) | – | |
| Asian: 5 (5) | – | |
| Other: 7 (6) | – | |
| Unknown: 11 (10) | – | |
| Ethnicity | Hispanic/Latino: 20 (18) | – |
| Not Hispanic/Latino: 79 (72) | – | |
| Unknown/Declined: 10 (9) | – | |
| Weight in kg | 78.0 [24.5] | 40.8–129.6 |
| BMI in kg/m2 | 27.86 [6.68] | 17.7–49.4 |
| Type II diabetes | 35 (32) | – |
| Hypertension | 59 (54) | – |
| Dyslipidemia | 55 (50) | – |
| Heavy alcohol use | 24 (22) | – |
| Smoking | 49 (46) | – |
| Total bilirubin in mg/dL | 0.5 [0.4] | 0.1–3.2 |
| AST in U/L | 37 [43] | 10–397 |
| ALT in U/L | 39 [48] | 7–444 |
| Alkaline Phosphatase in U/L | 95 [77] | 37–845 |
| Platelets count ×103/µL | 197 [106] | 55–412 |
| INR | 1.1 [0.2] | 0.88–2.7 |
| Albumin in g/dL | 4.4[0.5] | 1.3–5.3 |
| Creatinine in mg/dL | 0.93 [0.67] | 0.5–10.0 |
| Liver disease etiology | NAFLD: 49 (45) | – |
| Hepatitis C: 16 (15) | – | |
| Congestive: 15 (14) | – | |
| Non-specific: 10 (9) | – | |
| Autoimmune: 9 (8) | – | |
| Normal: 8 (7) | – | |
| Post-transplant: 7 (6) | – | |
| Other: 6 (6) | – | |
| PBC: 5 (5) | – | |
| Alcoholic liver disease: 4 (4) | – | |
| NRH: 4 (4) | – | |
| Hepatitis B: 3 (3) | – | |
| # of Etiologies/Subject | 1: 87 (80) | – |
| 2: 17 (16) | – | |
| 3: 5 (5) | – | |
| Biopsy fibrosis stage | Stage 0: 35 (32) | – |
| Stage 1: 23 (21) | – | |
| Stage 2: 19 (17) | – | |
| Stage 3: 20 (18) | – | |
| Stage 4: 12 (11) | – |
†For continuous variables (for example, age, AST, albumin), values are medians followed by [IQR]. For categorical variables (for example, sex, hypertension, biopsy fibrosis stage), values are number of patients in each category follow by (percentage). ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; NRH, nodular regenerative hyperplasia; PBC, primary biliary cholangitis.